Introduction
Platelet adhesion and subsequent aggregation at sites of vascular injury are key events required to arrest bleeding. However, the same hemostatic processes may also contribute to the generation of inopportune thrombi within atherosclerotic arteries. It has been demonstrated that von Willebrand factor (VWF) and fibrinogen (Fg) are two essential molecules that mediate platelet adhesion and aggregation [1] . Deficiencies in either of these molecules are associated with bleeding disorders [i.e. von Willebrand disease (VWD) and afibrinogenemia]. Although no Fg/VWF double-deficient patients have been reported, our data have shown that Fg/ VWF )/) mice are viable and form occlusive thrombi after vascular injury [2] . The molecular basis for thrombosis and hemostasis independent of VWF and Fg is, however, largely unknown. The molecules involved in platelet adhesion and aggregation have been intensively studied. It has been demonstrated that the platelet membrane glycoprotein (GP) Ib complex and its ligand, VWF, initiate platelet adhesion, particularly at high shear [1, [3] [4] [5] . Subsequent stable adhesion is mediated by several platelet integrin receptors and their ligands (e.g. integrin a 2 b 1 /collagen, integrin a IIb b 3 /Fg and VWF) as well as interaction between GPVI and collagen [1, 4, 6] . Following initial adhesion, additional platelets aggregate on the layer of adherent platelets to form a hemostatic plug. This is probably mediated by the synergistic action of several platelet receptors and their ligands, including a IIb b 3 /Fg [7, 8] , a IIb b 3 /VWF, GPIb complex/VWF [1, 9, 10] , P-selectin/sulfatides [11] , and b 1 integrin/fibronectin (Fn) [4, 12] . In addition, glycolipids, heparans, proteoglycans, and SLAM family receptors may also be involved in this process [13, 14] .
It has been well-demonstrated in vitro that Fg is required for platelet aggregation both in afibrinogenemic patients and in gene-deficient animals [15, 16] . This suggests that bridging ligands other than Fg may play either a minor role or a secondary role following Fg engagement during platelet aggregation. It is intriguing, therefore, that platelet-rich thrombi are able to form in mice lacking Fg and, even more surprisingly, in mice lacking both Fg and VWF [2] . In addition, although it has been reported that a IIb b 3 integrin plays a central role in platelet aggregation [8, 17] , platelets from Glanzmann thrombasthenic patients lacking a IIb b 3 proteins are still able to aggregate, suggesting that b 3 integrin-independent platelet aggregation exists [13, 18] . Furthermore, thrombus formation occurs in b 3 )/) mice [19] , although it is not clear whether platelet aggregation is involved in this process. Thus, it is of interest to investigate whether b 3 integrin is required for Fg/VWF-independent platelet aggregation.
In this study, we investigated the mechanism of Fg/VWFindependent platelet aggregation by performing in vitro aggregation assays and in vivo intravital microscopy. We first observed robust adenosine diphosphate (ADP)-induced Fg/ VWF-independent platelet aggregation in non-anticoagulated plasma in vitro. Further experiments using b 3 )/) platelets and different thrombin inhibitors demonstrated that both b 3 integrin and thrombin were critical for this aggregation. Moreover, both plasma and platelet granule-released proteins contributed synergistically to this novel platelet aggregation pathway.
Material and methods

Experimental animals
Fg/VWF )/) mice and b 3 )/) mice have been previously described [2, 20] . b 3 )/) mice were backcrossed onto the BALB/c background at the Massachusetts Institute of Technology. Syngeneic BALB/c and C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and used as controls. Genotypes of all experimental animals were confirmed by polymerase chain reaction analysis. All animal care and experimental procedures were approved by the Animal Care Committee at St Michael's Hospital.
Platelet and plasma preparation
Mice (6-8 weeks old) were anesthetized and bled from the retro-orbital plexus using heparin-coated glass capillary tubes. The blood was collected into a tube containing 3% acid citrate dextrose (ACD; 1/9, v/v) or 3.8% sodium citrate (1/9, v/v). Platelet-rich plasma (PRP) was obtained by centrifugation at 300 · g for 7 min. Platelets were isolated from the PRP (ACD used as an anticoagulant) using a Sepharose 2B column in PIPES buffer (PIPES 5 mM, NaCl 1.37 mM, KCl 4 mM, glucose 0.1%, pH 7.0) [2, 21] . Plateletpoor plasma (PPP) was prepared from Fg/VWF )/) mouse whole blood with or without anticoagulant, as previously described [21] .
Platelet aggregation
Platelet aggregation was performed at 37°C using a computerized Chrono-log aggregometer (Chrono-Log Corporation, Havertown, PA, USA). The method of platelet aggregation in anticoagulated PRP has been previously described [21] . . Platelet aggregates were observed under a Zeiss Axiovert 135-inverted microscope (32X, 0.4NA; Zeiss, Oberkochen, Germany) and pictures were taken with a digital camera (DP70, Olympus, Japan).
Detection of GPIba, b1 integrin and P-selectin on the platelet surface Resting gel-filtered platelets (10 6 ) from wild-type (BALB/c) and b 3 )/) mice were incubated for 30 min with rat anti-mouse GPIba antibody p0p5 (10 lg mL , provided by B. Nieswandt, University of Wurzburg, Germany) in 50 lL of PIPES buffer. The expression of GPIba was detected with fluorescein isothiocyanate (FITC)-conjugated anti-rat polyvalent immunoglobulin G (1:100; Sigma-Aldrich). Similar samples were incubated with FITC-conjugated hamster anti-rat CD29 (antib 1 integrin) that crossreacts with mouse b 1 integrin (1:100; BD Pharmingen, San Jose, CA, USA) to detect the expression of b 1 integrin. In order to examine P-selectin expression on platelet surfaces, resting or activated (1 U mL )1 thrombin or 20 lM ADP) platelets were incubated with FITC-conjugated rat anti-mouse CD62P (P-selectin, BD Pharmingen). All samples were analyzed by a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
In vivo intravital microscopy thrombosis model
Intravital microscopy was performed as previously described [2, 21] . Briefly, platelets were isolated from donor Fg/VWF , b 3 )/) or b 3 +/+ platelets (2.5 · 10 6 g
)1
), as described above. Thrombus formation was induced with FeCl 3 and pictures were taken with the digital camera DP70 combined with a confocal cell imaging module (BD Biosciences, Rockville, MD, USA) under the intravital fluorescence microscope. We monitored several independent arterioles and venules within the same mouse as well as in comparison with different mice.
Statistical analysis
Data are presented as mean ± SEM. Statistical significance was assessed by unpaired Student's t-test.
Results
Fg/VWF
)/) platelets aggregated in vitro in non-anticoagulated
To elucidate the pathway of thrombus formation in Fg/VWF
mice [2] , we examined platelet aggregation in vitro. Using a routine method for PRP preparation with 3% ACD, ADP was capable of inducing platelet aggregation in wild-type and
Similar results were obtained using either 3.8% sodium citrate as an anticoagulant (Fig. 1B) or citrated PRP after the pH was adjusted to 7.3-7.5 with NaOH (data not shown). As there is no fibrin formation in Fg/VWF )/) mice, we next prepared Fg/ VWF )/) plasma without adding exogenous anticoagulant.
When this non-anticoagulated plasma was mixed with gelfiltered Fg/VWF )/) platelets, robust aggregation occurred following ADP stimulation ( Fig. 2A) .
Because it was reported that platelet aggregation occurs with platelets from patients lacking a IIb b 3 proteins [13, 18] , we reasoned that Fg/VWF )/) platelet aggregation may occur in either a b 3 integrin-dependent or -independent manner. Therefore, we examined whether Fg/VWF-independent platelet aggregation in vitro was mediated by b 3 integrin. As shown in Fig before and after thrombin (1 or 10 U mL ) stimulation (Fig. 2B ). There was also no reduction of these receptors on wild-type BALB/c platelets as compared with Fg/VWF )/) platelets (C57BL/6J/129 background, data not shown). These results excluded the possibility that GPIba, b 1 integrins or Pselectin deficiency was responsible for the inability of b 3
platelets to aggregate. As shown in Fig. 2A , ADP-induced Fg/VWF )/) platelet aggregates did not exhibit significant deaggregation, which suggested that platelet granule release probably occurred [22] . As we did not add exogenous anticoagulant during preparation of the plasma in these experiments, trace amounts of thrombin may have remained in the plasma, which may promote ADPinduced thrombin generation on the platelet surface [23] . heparin, hirudin or PPACK. These data confirm that inhibition of aggregation by heparin, hirudin or PPACK was thrombinspecific and that thrombin receptor activation induced Fg/ VWF-independent platelet aggregation.
Hirudin inhibited Fg/VWF )/) thrombus formation in vivo
We then used intravital microscopy to investigate the effect of hirudin (3 mg kg
) on platelet aggregation and thrombus formation in Fg/VWF )/) mice (Fig. 4C) . The number of early single platelets deposited at the site of injury was not significantly different between hirudin-treated and untreated Fg/VWF )/) mice. Approximately 5-10 min after injury, platelets adhered more stably to the vessel wall and started to form visible platelet aggregates in untreated Fg/VWF )/) mice.
However, we did not observe any apparent platelet aggregates in hirudin-injected mice during the 40 minute experiments. These data differ from those in hirudin-injected wild-type mice, in which platelet aggregation and thrombus formation occur [24] . Thus, thrombin is required for Fg/VWF-independent platelet aggregation in vivo.
Both platelet granule and plasma protein(s) contributed to Fg/VWF )/) platelet aggregation
Because Fg/VWF )/) platelet aggregation was dependent on thrombin signaling, it is possible that granule release may play an important role in this aggregation pathway. To test this possibility, we induced platelet aggregation with additional strong and weak agonists. As shown in Fig. 5 , high-dose (20 lg mL A23187 (10 lm) were also able to induce Fg/VWF )/) platelet aggregation in Fg/VWF )/) plasma (hirudin-anticoagulated).
The same results were obtained when PPACK was used as the anticoagulant. However, weak agonists such as epinephrine and low-dose (2 lg mL )1
) collagen did not induce this aggregation (data not shown).
To distinguish between the contribution of platelet granule proteins and plasma proteins, we analyzed gel-filtered Fg/ VWF )/) platelet aggregation in PIPES buffer. No Fg/VWF )/) platelet aggregation was induced by ADP in this buffer. There was also no significant aggregation after either thrombin (1 U mL
) or TRAP (500 lM) treatment. However, after adding 1 mM CaCl 2 to the PIPES buffer, both thrombin and TRAP, but not ADP, induced Fg/VWF )/) platelet aggregation (Fig. 6A,B) . Concomitantly, we found that P-selectin, a marker for granule release, was expressed on the Fg/VWF )/) platelet surface after either 1 U mL )1 thrombin (Fig. 6C, left panel) or 500 lM TRAP treatment, but was not expressed after ADP (20 lM) treatment in 1 mM Ca 2+ PIPES buffer. Similar results were also observed in micro-aggregates from thrombin-induced platelet aggregation (Fig. 6C, right panel) . It is notable that ADP was also not able to induce P-selectin expression on wild-type platelets in the same PIPES buffer (data not shown). Together, these data suggest that platelet granule protein(s) contributed to Fg/VWF-independent platelet aggregation. It appears that this process requires millimolar levels of Ca 2+ and the moderate levels of platelet-released Ca 2+ are insufficient to support this aggregation in PIPES buffer. Notably, there was no significant enhancement of aggregation after adding higher doses of Ca 2+ and/or Mg PPP (Figures 2A and 6 ). As shown in Fig. 6 , thrombininduced Fg/VWF )/) platelet aggregation in PIPES buffer (41.3 ± 5.9%, n ¼ 3) was less than that in Fg/VWF )/) plasma (73.0% ± 7.2%, n ¼ 3; P < 0.05); TRAP-induced Fg/ VWF )/) platelet aggregation in PIPES buffer (44.7% ± 2.9%, n ¼ 3) was also less than that in hirudinpretreated Fg/VWF )/) plasma (73.3% ± 5.9%, n ¼ 3; P < 0.05). In addition, thrombin-or TRAP-induced Fg/ VWF )/) platelet aggregation in 1 mM CaCl 2 PIPES buffer was also less than ADP-induced aggregation in Fg/VWF )/) PRP (Figures 2A and 6A,B) . Furthermore, platelet aggregates that formed following thrombin or TRAP stimulation in PIPES buffer were considerably smaller than those in Fg/VWF )/) plasma (Fig. 6A,B) . In fact, the extent of Fg/VWF )/) platelet aggregation and the morphology of these aggregates in Fg/ VWF )/) plasma (Fig. 6A,B) were indistinguishable from their wild-type controls (data not shown). Dose-response experiments showed that the 1 U mL )1 thrombin or 500 lM TRAP used in the gel-filtered platelet aggregation in PIPES buffer achieved a platelet aggregation plateau, and no further enhancement of aggregation was observed with higher con- mouse arterioles eventually occluded. Lower panel: in the hirudin-injected group, no significant difference was found in the platelet-vessel wall interaction during the first 3-5 min when compared with the non-hirudininjected group. Platelet aggregation and thrombus formation were completely inhibited in hirudin-treated arterioles.
centrations of thrombin (2 and 4 U mL ) or TRAP (1 mM). These data suggest that both plasma and platelet granule proteins contributed to the Fg/VWF-independent platelet aggregation.
Discussion
Fibrinogen is considered an essential bridging molecule for platelet aggregation [8, 15, 16, 25] . In patients with afibrinogenemia, residual platelet aggregation is thought to be mediated mainly by VWF [26] . However, we demonstrated here that under more physiological conditions (i.e. non-anticoagulated plasma), robust platelet aggregation occurs in the absence of both Fg and VWF in vitro. We further demonstrated that Fg/ VWF-independent platelet aggregation is dependent on b 3 integrin, thrombin, platelet secretion and divalent Ca 2+ cations. Both plasma and platelet granule proteins contribute to this novel pathway of platelet aggregation.
The critical role of Fg in platelet aggregation was established by studying specimens from patients with afibrinogenemia (< 200 lg mL )1 Fg in their plasma) [15, 27] . However, because significant residual Fg exists in most afibrinogenemic blood, exogenous anticoagulant reagents, such as sodium citrate, are routinely used to prevent coagulation during blood preparation. Under these circumstances, afibrinogenemic PRP responded poorly to ADP-induced aggregation. De Marco et al. [26] reported that the monoclonal antibody LJP5, which specifically blocks VWF/a IIb b 3 interaction but not Fg/a IIb b 3 interaction, was able to abolish residual platelet aggregation in afibrinogenemic citrated-PRP. As some residual Fg was present in both the plasma and platelets in these cases, it is thus not clear whether residual Fg is required to initiate this VWF-mediated platelet aggregation. It remains unclear, therefore, whether Fg-independent aggregation indeed occurs in citrated blood, and whether Fg/VWF-independent aggregation can be induced in non-anticoagulated blood. Our Fg/VWF-double deficient mice (in which Fg and VWF are completely deleted) provided an opportunity to study Fgand VWF-independent platelet aggregation, particularly under more physiological conditions where the effects of anticoagulant reagents were minimized. The data presented in this study differ from the aggregation data seen in the afibrinogenemic patients who have residual Fg. We demonstrated that Fg, at least in murine blood, is probably an indispensable bridging molecule for platelet aggregation in anticoagulated blood (Figs 1 and  4A ). However, under more physiological conditions (i.e. nonanticoagulated blood), robust platelet aggregation can be induced in the absence of both Fg and VWF (Fig. 2) .
Is b 3 integrin required for this Fg/VWF-independent platelet aggregation? It has been reported that platelet aggregation occurs in patients lacking a IIb b 3 integrin (type I Glanzmann thrombasthenia) [13, 18] . We also found a very low level of platelet aggregation (< 10% of normal level) in gel-filtered b 3 )/) platelets in PIPES buffer after stimulation with thrombin (unpublished data). These observations are consistent with the concept that multiple platelet receptors may be involved in platelet aggregation [4, [10] [11] [12] [13] [14] . However, in the present study, using b 3 )/) mice as well as our newly developed anti-mouse b 3 integrin blocking antibody (data not shown), we found that b 3 integrin is the essential receptor that mediates this Fg/VWFindependent platelet aggregation (Figs 2 and 3) . What are the ligand(s) mediating Fg/VWF-independent platelet aggregation? Fn [28] , thrombospondin-1 (TSP-1) [29] , vitronectin (Vn) [21] , and CD40L [30] may be candidates. We recently demonstrated that plasma Fn promotes thrombus growth and stability [12] . It is as yet unclear, however, whether this results from Fn supporting platelet aggregation, stabilizing the fibrin clot, or self-assembling [31, 32] . We are also not certain whether this results from plasma Fn or platelet granule Fn. The latter comes mainly from plasma via b 3 integrin internalization [33] . mice [2, 33] . We recently found that released platelet vitronectin significantly supported platelet aggregation, although plasma vitronectin inhibited this process [21] . Thus, platelet Fn, vitronectin and TSP-1, as well as other ligands such as CD40L, may synergistically contribute to this Fg/VWFindependent platelet aggregation after treatment with a potent agonist. We found that thrombin is critical for Fg/VWF-independent platelet aggregation in vitro and in vivo (Fig. 4) . Interestingly, although thrombin inhibitors do not affect ADP-induced a IIb b 3 activation and subsequent ligand binding [34] , they did inhibit ADP-induced Fg/VWF )/) platelet aggregation in plasma (Fig. 4A ). This suggested that ADP might play a key role, e.g. via interaction with its receptor P2Y 12 [35] , in Fg/VWF )/) platelet aggregation, by inducing thrombin generation.
We also found that physiological (mM) levels of Ca 2+ ions were required for Fg/VWF )/) platelet aggregation and that small amounts of platelet-released Ca 2+ were insufficient to support this aggregation. This is intuitive because b 3 integrin is required for this new pathway of platelet aggregation and both the b-propeller and MIDAS domains of integrins require Ca 2+ in order to maintain structural integrity. Although the Fg/ a IIb b 3 and VWF/a IIb b 3 interactions may be less dependent on divalent cations and are able to bridge platelets in citrated plasma, other ligands, such as Fn, bind to b 3 integrin in a divalent cation-dependent manner [36] . It is very likely that physiological levels of Ca 2+ (but not the residual levels present in citrated plasma) may be required to maintain the appropriate conformation of b 3 integrin for recognition of other ligands (i.e. ligands other than Fg and VWF). Furthermore, in the processes of ADP-induced thrombin generation and platelet degranulation, Ca 2+ may also be required. Thus, citrated blood, as used in earlier studies, may mask the interaction between b 3 integrin and other plasma and platelet granule ligands.
In summary, the current theory that Fg and VWF are essential for platelet aggregation was established based on studies using anticoagulated blood in vitro, which may differ from pathophysiological conditions in vivo. At the site of injury, including the rupture of an atherosclerotic plaque, thrombin, divalent cations, and other platelet agonists are present, which may allow b 3 integrin to bind ligands other than Fg and VWF. These ligands may play an important role in supporting hemostasis in VWD and afibrinogenemia, and may also contribute to the thrombotic process in normal individuals. Identification and characterization of these ligands should be of great interest for future studies.
